Form 4: Amicus CFO Disposes Shares for Tax Obligations

Amicus Therapeutics' Chief Financial Officer, Simon N.R. Harford, reported the disposition of 12,529 common shares at $7.60 each, primarily for tax withholding purposes.

Summary

• Simon N.R. Harford, Chief Financial Officer of Amicus Therapeutics, Inc. (FOLD), reported a disposition of common stock.
• On August 21, 2025, 12,529 shares of common stock were disposed of at a price of $7.60 per share.
• The transaction code 'F' indicates that these shares were disposed of to cover tax withholding obligations related to the vesting of equity awards.
• Following this transaction, Mr. Harford beneficially owns 214,898 shares of Amicus Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary disposition of shares for tax withholding purposes upon the vesting of equity awards. While it reduces insider ownership, it is not indicative of a discretionary sell-off and is generally considered neutral in terms of market sentiment.

Positives

• The transaction is a non-discretionary event, typically related to the vesting of equity awards, indicating the executive is still holding a significant number of shares.

Negatives

• A reduction in direct beneficial ownership by a key executive, even if for tax purposes, slightly decreases insider alignment.

Future Outlook

NA

Industry Context

This is a routine insider transaction and does not provide specific industry context beyond the company's operations.

Related Party Transactions

• Disposition of 12,529 common shares by Chief Financial Officer Simon N.R. Harford to Amicus Therapeutics, Inc. for tax withholding purposes at $7.60 per share.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but for a non-discretionary tax purpose, which is generally not viewed negatively.
• Employees: No direct impact on employees beyond the executive involved.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary disposition of shares by the CFO to cover tax obligations upon the vesting of equity awards. It does not signal a change in the company's fundamentals or the executive's confidence in the company, thus it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Amicus Therapeutics, FOLD, Simon N.R. Harford, CFO, Insider Trading, Form 4, Stock Disposition, Tax Withholding, Equity Awards